# Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

> **NCT03802396** · PHASE2 · COMPLETED · sponsor: **Miles Berger, MD PhD** · enrollment: 203 (actual)

## Conditions studied

- Postoperative Delirium
- Postoperative Cognitive Dysfunction

## Interventions

- **DRUG:** CN-105
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03802396
- **Lead sponsor:** Miles Berger, MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-15
- **Primary completion:** 2022-12-28
- **Final completion:** 2022-12-28
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03802396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03802396, "Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03802396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*